Lung Cancer Trials Ask AI to find trials
CompletedPhase 1NCT01121575
Official study title

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Study summary

Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and the EGFR pathway. Both resistance mechanisms can occur at the same time, in the same patient and even in the same tumor. This study combines a second generation EGFR inhibitor and a cMET inhibitor to block both these pathways in order to overcome resistance and treat this disease.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedPF-02341066 and PF-00299804

Plus 2 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Small cell lung cancer (SCLC) · EGFR

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 28, 2015 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?10 U.S. locations

Locations may change over time.

Who runs it?Pfizer

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Pfizer
Interventions being studied
Drug: PF-02341066; Drug: PF-00299804; Drug: PF-02341066; Drug: PF-00299804
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→Small cell lung cancer (SCLC)→
Biomarkers
EGFR→MET→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • advanced non small cell lung cancer (dose escalation phase)
  • acquired resistance to erlotinib or gefitinib (expansion phase)
  • mandatory entrance biopsy (expansion phase)
Reasons someone may not be able to joinExclusion criteria
  • interstitial lung disease
  • unstable brain metastases
  • leptomeningeal disease

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Clinical Trials Office University of Colorado Hospital (CTO)Aurora, Colorado
  • DRUG SHIPMENT: University of Colorado Cancer CenterAurora, Colorado
  • Rocky Mountain Lions Eye InstituteAurora, Colorado
  • University of Colorado HospitalAurora, Colorado
  • CCR, National Cancer InstituteBethesda, Maryland
  • Drug Shipment OnlyBoston, Massachusetts
  • Massachusetts General HospitalBoston, Massachusetts
  • Brigham & Women's HospitalBoston, Massachusetts
  • Drug Shipment OnlyBoston, Massachusetts
  • Peter MacCallum Cancer Centre, Division of Haematology and Medical OncologyEast Melbourne, Victoria

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 28, 2015. Always confirm current availability with the study team.

View original record ↗